Page last updated: 2024-08-23

bezafibrate and Hyperlipoproteinemia Type II

bezafibrate has been researched along with Hyperlipoproteinemia Type II in 68 studies

Research

Studies (68)

Timeframe	Studies, this research(%)	All Research%
pre-1990	45 (66.18)	18.7374
1990's	20 (29.41)	18.2507
2000's	3 (4.41)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R	1
Boag, DE; Lorimer, AR; Packard, CJ; Shepherd, J; Stewart, JM	1
Arntz, HR; Bräuning, C; Hansen, W; Middelhoff, G; Schlierf, G; Vollmar, J; Wirth, A	1
Franceschini, G; Paoletti, R; Sirtori, CR	1
Bartnikowska, E; Michajlik, A; Wegrzyn, B	1
Bartosiewicz, W; Ilińska-Debniak, K; Stryjek-Kamińska, D; Szczepanik, Z	1
Sznajderman, M	1
Chwistecki, K; Kopel, E; Mrukowicz, M	1
Kurlat, MI; Neuman, J; Neuman, MP	1
Kokot, F; Szczechowska, E	1
Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K	1
Ledermann, H; Lithell, H; Vessby, B	1
Braeuning, C; Middelhoff, G; Schlierf, G; Wirth, A	1
Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG	2
Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R	1
Bachmann, C; Fragiacomo, C; Noseda, G; Weidmann, P	1
Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W	1
Mertz, DP	1
Eliav, O; Friedlander, Y; Leitersdorf, E; Pfister, P; Schurr, D	1
Eliav, O; Leitersdorf, E; Muratti, EN; Peters, TK	1
Abate, N; Bertolotti, M; Carulli, N; Concari, M; Guicciardi, ME; Loria, P; Pinetti, A	1
Dann, EJ; Eisenberg, S; Eliav, O; Leitersdorf, E; Meiner, V; Muratti, EN; Peters, TK; Sehayek, E; Stein, Y	1
Leitersdorf, E; Muratti, EN; Peters, TK	1
Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D	1
Cassader, M; Gambino, R; Niort, G; Pagano, G	1
Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W	1
Hailer, S; Keller, C; Pogarell, O; Wolfram, G	1
Betteridge, DJ; O'Bryan-Tear, CG	1
Arrol, S; Bhatnagar, D; Durrington, PN; Julier, K; Mackness, MI; Morgan, J; Prais, H; Wood, GN	1
Bergemann, R; Brandt, A; Siegrist, W	1
de Man, FH; Mohrschladt, MF; Smelt, AH; Stoeken, DJ; Sturk, A; Westendorp, RG; Weverling-Rijnsburger, AW	1
Boschetti, C; Cofrancesco, E; Cortellaro, F; Cortellaro, M; Mancini, M; Mariani, M; Paoletti, R	1
Bolzano, K; Krempler, F; Schellenberg, B; Schlierf, G	1
Holzgartner, H; Kuhn, U; Schmidt, U	1
Breier, C; Eber, B; Gaul, G; Klein, W; Schmidt, P; Schumacher, M; Silberbauer, K; Stühlinger, W	1
Bednarska-Makaruk, M; Broda, G; Chotkowska, E; Kurjata, P; Kuźmińska, A; Polakowska, M; Rywik, S	1
Bradford, RH; Goldberg, AC; Knopp, RH; Schonfeld, G	1
Becker, M; Staab, D; Von Bergman, K	1
Arntz, HR; Bönner, G; Kikis, D; Kirch, W; Klör, HU; Lederle, RM; Overlack, A; Steinmetz, A; Stumpe, KO	1
Császár, A; Karádi, I; Köszegi, G; Németh-Csóka, M; Pados, G; Pichler, M; Romics, L	1
Carlson, LA	1
Saito, Y; Yoshida, S	1
Hodgetts, TJ; Tunnicliffe, C	1
Avogaro, P; Bittolo Bon, G; Bufalino, L; Cazzolato, G; Soldan, S	1
Acacia, E; Jones, C; Kremer, P; Marowski, C	1
Daher, E; Dakak, N; Khoury, K; Yeshurun, D	1
Bojanovski, D; Bojanovski, M; Canzler, H; Jochim, A; Schulzeck, P	1
Bonfiglioli, D; Branchi, A; Fasoli, A; Orlandi, S; Pini, C; Scandiani, L; Sommariva, D; Tirrito, M	1
Bonaiuto, M; Cinquegrani, M; Fodale, P; Lanzafame, F; Mazza, G; Micali, G; Mileto, A; Pangallo, A; Pernice, F; Saitta, A	1
Bard, JM; Devulder, B; Douste-Blazy, P; Fruchart, JC; Harvengt, C; Lecerf, JM; Leclerc, V	1
Betteridge, J; Curtis, LD; Dickson, AC; Ling, KL	1
Eisenberg, S; Fainaru, M; Gavish, D; Oschry, Y	1
Bakir, R; Chanu, B; Djian, F; Gomberg, R; Goy-Loeper, J; Laval-Jeantet, M; Monsuez, JJ; Rouffy, J	1
Weisweiler, P	1
Hunninghake, DB; Peters, JR	1
Palmer, RH	1
Postiglione, A; Riccardi, G; Saldalamacchia, G	1
Karádi, I; Köszegi, G; Kusztos, R; Németh Csóka, M; Pados, G; Romics, L; Szám, I	1
Balabanski, L; Goranov, I; Kerekovska, M; Naumova, R	1
Bachórzewska-Gajewska, H; Borowska, A; Kaliciński, A	1
Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M	1
Leiss, O; Meyer-Krahmer, K; von Bergmann, K	1
Kłosiewicz-Latoszek, L; Naruszewicz, M; Nowicka, G; Szostak, WB	1
Barley, J; Lloyd, JK; West, RJ; Wheeler, KA	1
Bachmann, C; Fragiacomo, C; Noseda, G; Schiffl, H; Weidmann, P	1
Lang, PD; Olsson, AG; Vollmar, J	1
Bellintani, L; Bonfiglioli, D; Branchi, A; Ottomano, C; Pogliaghi, I; Sommariva, D; Tirrito, M	1

Reviews

2 review(s) available for bezafibrate and Hyperlipoproteinemia Type II

Article	Year
Effect of fibric acid derivatives on blood lipid and lipoprotein levels. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids	1987
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987

Trials

35 trial(s) available for bezafibrate and Hyperlipoproteinemia Type II

Article	Year
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Medical science monitor : international medical journal of experimental and clinical research, 2003, Volume: 9, Issue:3 Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1	2003
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels. The American journal of cardiology, 1983, Aug-22, Volume: 52, Issue:4 Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship	1983
[Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1983, Sep-26, Volume: 38, Issue:39 Topics: Adult; Ambulatory Care; Bezafibrate; Clinical Trials as Topic; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Middle Aged	1983
[Effect of bezafibrate on disorders of lipid metabolism]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1983, Dec-12, Volume: 38, Issue:50 Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides	1983
[Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV]. Przeglad lekarski, 1984, Volume: 41, Issue:7 Topics: Adult; Aged; Bezafibrate; Cholesterol; Clinical Trials as Topic; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Propionates; Triglycerides	1984
[Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV]. Przeglad lekarski, 1984, Volume: 41, Issue:9 Topics: Bezafibrate; Clinical Trials as Topic; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV	1984
[Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1981, Jul-01, Volume: 36, Issue:13 Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Random Allocation; Triglycerides	1981
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV]. Die Medizinische Welt, 1982, Apr-30, Volume: 33, Issue:17 Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates	1982
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar. Atherosclerosis, 1982, Volume: 45, Issue:3 Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Female; Galactans; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Mannans; Middle Aged; Plant Gums; Polysaccharides	1982
High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. The American journal of cardiology, 1995, Jul-13, Volume: 76, Issue:2 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Delayed-Action Preparations; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Longitudinal Studies; Placebos; Safety; Triglycerides	1995
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. The American journal of cardiology, 1995, Jul-13, Volume: 76, Issue:2 Topics: Adult; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Artery Disease; Creatine Kinase; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Kidney; Liver; Male; Middle Aged; Patient Compliance; Placebos; Safety; Triglycerides	1995
Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. The American journal of medicine, 1994, Volume: 96, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Drug Combinations; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hyperlipoproteinemia Type II; Indoles; Male; Middle Aged; Myositis; Placebos; Safety; Single-Blind Method; Triglycerides	1994
Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment. The American journal of cardiology, 1994, May-26, Volume: 73, Issue:14 Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Cohort Studies; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lipids; Lipoproteins; Male; Middle Aged; Retrospective Studies; Time Factors	1994
Bezafibrate affects lipid, lipo- and apolipoprotein pattern in non-insulin-dependent diabetic patients. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1993, Volume: 25, Issue:7 Topics: Apolipoproteins; Bezafibrate; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Single-Blind Method	1993
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. Clinical cardiology, 1995, Volume: 18, Issue:11 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides	1995
Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia. Arzneimittel-Forschung, 1996, Volume: 46, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Blood Protein Electrophoresis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Indoles; Lipoproteins, HDL; Male; Middle Aged	1996
Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. Postgraduate medical journal, 1996, Volume: 72, Issue:854 Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Delayed-Action Preparations; Female; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Triglycerides	1996
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, Volume: 138, Issue:1 Topics: Adult; Aged; Aryldialkylphosphatase; Bezafibrate; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Double-Blind Method; Esterases; Female; Fibrinogen; Gemfibrozil; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Plasminogen Activators	1998
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy. Atherosclerosis, 2000, Volume: 148, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Reference Values	2000
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Trea Thrombosis and haemostasis, 2000, Volume: 83, Issue:4 Topics: Adult; Aged; Bezafibrate; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Tissue Plasminogen Activator; Treatment Outcome	2000
Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate. Arzneimittel-Forschung, 1992, Volume: 42, Issue:12 Topics: Aged; Bezafibrate; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Garlic; Heart Rate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemias; Male; Middle Aged; Odorants; Plants, Medicinal; Triglycerides	1992
Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia. Acta medica Austriaca, 1992, Volume: 19, Issue:5 Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Combined Modality Therapy; Delayed-Action Preparations; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Triglycerides	1992
[Effect of bezafibrate on serum lipid, lipoprotein and apoprotein levels in patients with hyperlipoproteinemia type II and IV]. Polskie Archiwum Medycyny Wewnetrznej, 1992, Volume: 87, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, VLDL; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides	1992
Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis, 1992, Volume: 92, Issue:1 Topics: Adolescent; Adult; Aged; Bezafibrate; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lipids; Lipoproteins; Male; Middle Aged	1992
[Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia]. Deutsche medizinische Wochenschrift (1946), 1991, Jan-04, Volume: 116, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Triglycerides	1991
A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia. Drugs under experimental and clinical research, 1989, Volume: 15, Issue:6-7 Topics: Adult; Aged; Benzhydryl Compounds; Bezafibrate; Delayed-Action Preparations; Female; Hemodynamics; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Randomized Controlled Trials as Topic	1989
Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb. Current medical research and opinion, 1989, Volume: 11, Issue:5 Topics: Adult; Aged; Argentina; Arteriosclerosis; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Triglycerides	1989
Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet (London, England), 1988, Mar-19, Volume: 1, Issue:8586 Topics: Adult; Aged; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides	1988
Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia. BMJ (Clinical research ed.), 1988, Jul-16, Volume: 297, Issue:6642 Topics: Adult; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Random Allocation	1988
Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia. European journal of clinical pharmacology, 1988, Volume: 35, Issue:6 Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Male; Middle Aged; Random Allocation; Simvastatin; Sterol O-Acyltransferase	1988
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987
Hypolipidemic effects of bezafibrate: studies in Italy. Monographs on atherosclerosis, 1986, Volume: 14 Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Lipids; Lipoproteins; Random Allocation	1986
[Effect of bezafibrate therapy on serum and lipoprotein lipids]. Orvosi hetilap, 1986, Oct-05, Volume: 127, Issue:40 Topics: Bezafibrate; Cholesterol, HDL; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins, LDL; Male; Middle Aged; Triglycerides	1986
Double blind trial of bezafibrate in familial hypercholesterolaemia. Archives of disease in childhood, 1985, Volume: 60, Issue:1 Topics: Adolescent; Bezafibrate; Child; Child, Preschool; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Male; Triglycerides	1985
[Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate]. Schweizerische medizinische Wochenschrift, 1985, Jun-29, Volume: 115, Issue:26 Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Creatine Kinase; Creatinine; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Long-Term Care; Male; Middle Aged; Placebos; Triglycerides	1985

Other Studies

32 other study(ies) available for bezafibrate and Hyperlipoproteinemia Type II

Article	Year
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis, 1982, Volume: 44, Issue:3 Topics: Adult; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Receptors, Cell Surface; Receptors, LDL	1982
[Effect of the combined administration of guar-bezafibrate on lipid, apolipoprotein and lipoprotein in patients with primary hyperlipoproteinemia type II]. Beitrage zu Infusionstherapie und klinische Ernahrung, 1983, Volume: 12 Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Combined Modality Therapy; Dietary Fiber; Female; Galactans; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Mannans; Middle Aged; Plant Gums	1983
Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate. Current medical research and opinion, 1983, Volume: 8, Issue:5 Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Triglycerides	1983
Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate. Atherosclerosis, 1982, Volume: 44, Issue:1 Topics: Adipose Tissue; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Muscles	1982
Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs. Artery, 1980, Volume: 8, Issue:6 Topics: Adolescent; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Inositol; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nicotinic Acids; Nicotinyl Alcohol; Xanthinol Niacinate	1980
Clinical experience with bezafibrate. Artery, 1980, Volume: 8, Issue:6 Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Triglycerides	1980
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]. Schweizerische medizinische Wochenschrift, 1980, Dec-06, Volume: 110, Issue:49 Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Lipoproteins, HDL; Triglycerides	1980
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs. Artery, 1980, Volume: 8, Issue:2 Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Inositol; Lipoproteins; Nicotinic Acids; Xanthinol Niacinate	1980
The effect of etofibrate retard, bezafibrate and procetofen. Artery, 1980, Volume: 8, Issue:2 Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides	1980
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. Fortschritte der Medizin, 1980, Dec-04, Volume: 98, Issue:45 Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged	1980
Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans. Arteriosclerosis, thrombosis, and vascular biology, 1995, Volume: 15, Issue:8 Topics: Adult; Bezafibrate; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged	1995
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin	1993
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson). PharmacoEconomics, 1993, Volume: 3, Issue:2 Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome	1993
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia]. Acta medica Austriaca, 1979, Volume: 6, Issue:3 Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Male; Middle Aged	1979
Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Pediatrics, 1992, Volume: 89, Issue:1 Topics: Apolipoprotein A-I; Bezafibrate; Child; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Male; Sitosterols; Triglycerides	1992
Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia. Klinische Wochenschrift, 1990, Volume: 68 Suppl 22 Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Triglycerides	1990
[A case of familial hypercholesterolemia with therapeutic difficulties]. Lakartidningen, 1990, Mar-07, Volume: 87, Issue:10 Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin	1990
[Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1989, Volume: 78, Issue:10 Topics: Anticholesteremic Agents; Bezafibrate; Blood Component Removal; Cholesterol; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Naphthalenes; Pravastatin; Probucol; Triglycerides	1989
Bezafibrate-induced headache. Lancet (London, England), 1989, Jan-21, Volume: 1, Issue:8630 Topics: Adult; Bezafibrate; Female; Headache; Humans; Hyperlipoproteinemia Type II; Time Factors	1989
[Acute severe myositis due to bezafibrate treatment]. Harefuah, 1989, Mar-01, Volume: 116, Issue:5 Topics: Acute Disease; Bezafibrate; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Kidney Diseases; Middle Aged; Myositis	1989
[Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia]. La Clinica terapeutica, 1987, Jul-15, Volume: 122, Issue:1 Topics: Apolipoproteins A; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Drug Evaluation; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Triglycerides	1987
[Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia]. La Clinica terapeutica, 1988, Mar-15, Volume: 124, Issue:5 Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Evaluation; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lipids; Male; Middle Aged; Time Factors; Triglycerides	1988
[Type IIa dyslipoproteinemia. Effects of simvastatin and bezafibrate on atherogenic and non-atherogenic lipoprotein particles]. Presse medicale (Paris, France : 1983), 1988, Dec-17, Volume: 17, Issue:45 Topics: Bezafibrate; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Simvastatin	1988
Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia. European journal of clinical investigation, 1986, Volume: 16, Issue:1 Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, LDL; Female; Humans; Hyperlipoproteinemia Type II; Lipase; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides	1986
Changes in lipid and lipoprotein levels and Achilles tendon diameters and indices in familial hypercholesterolaemic patients with tendinous xanthomatosis treated by diet and bezafibrate for 2 years. Current medical research and opinion, 1988, Volume: 11, Issue:2 Topics: Achilles Tendon; Adult; Bezafibrate; Cholesterol, Dietary; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Xanthomatosis	1988
[Indications for and the therapeutic action of hypolipidemic agents in patients with hyperlipoproteinemias]. Vutreshni bolesti, 1987, Volume: 26, Issue:1 Topics: Bezafibrate; Cholesterol; Drug Evaluation; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Nicotinyl Alcohol; Probucol; Triglycerides	1987
[Platelet aggregation in patients with hyperlipoproteinemia treated with bezafibrate]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1986, Mar-03, Volume: 41, Issue:9 Topics: Adult; Bezafibrate; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Platelet Aggregation	1986
Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients. International journal of clinical pharmacology research, 1986, Volume: 6, Issue:3 Topics: Adult; Bezafibrate; Cholesterol; Cholestyramine Resin; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged	1986
Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate. Journal of lipid research, 1986, Volume: 27, Issue:7 Topics: Adult; Bezafibrate; Bile; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Middle Aged; Phospholipids; Propionates; Triglycerides	1986
Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia. Atherosclerosis, 1987, Volume: 63, Issue:2-3 Topics: Adult; Aged; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemias; Lipoproteins; Male; Middle Aged; Polyamines	1987
Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. Atherosclerosis, 1985, Volume: 55, Issue:2 Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Patient Compliance; Time Factors; Triglycerides	1985
Changes in serum lipoprotein pattern following bezafibrate. Differential effects in type IIa and in type IIb hyperlipoproteinemic patients. Pharmacological research communications, 1985, Volume: 17, Issue:12 Topics: Adult; Aged; Bezafibrate; Cholesterol; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Triglycerides	1985